## **PATENT**



Attorney Docket No. NUCL-006/01US Application No. 10/560,377 (US Nat'l. Stage of PCT/US04/19229

Page 1

1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Catherine J. PACHUK et al.

Confirmation No.: 3823

Application No.: 10/560,377

Group Art Unit: To Be Assigned

Int'l. Filing Date: June 10, 2004

Examiner: To Be Assigned

For: Conserved HBV and HCV Sequences Useful for Gene Silencing

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window, Mail Stop Amendment
Randolph Building
401 Dulany Street
Alexandria, VA 22314

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)**

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

- [x] Pursuant to 37 C.F.R. §1.98, copies of documents 1-3 cited in the attached Form PTO-1449 are enclosed.
- [ ] Copies of the remaining publications listed on the attached Form PTO-1449 are not being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial Nos.: to which the above-identified application claims priority under 35 U.S.C. §120.
- [ ] Copies of documents that were not submitted in the above-mentioned related United States Patent Applications may be found in related United States Patent Application Nos.:
  - Should the Examiner be unable to locate a document, a copy will be provided upon request.
- [ ] No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO-1449 are being provided pursuant to 37 C.F.R. §1.98.

47893 v1/DC

[ ] Document is the PCT Patent publications of Applicants' related PCT Application no. \_\_\_\_\_, filed \_\_\_\_\_. [x]Documents 1 and 2 were cited in a Search Report mailed September 16, 2005 (cited herein as document 3), in Applicants' related PCT patent application no. PCT/US2004/019229, filed June 10, 2004. [x]Document 3 is an official communications from a foreign patent office received in Applicants' related PCT Application no. PCT/US2004/019229, filed June 10, 2004. [] Documents submitted herewith were not cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement. [ ] Enclosed is a copy of a non-English publication(s) \_\_\_. Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s). Enclosed is a copy of a non-English publication(s) . English language [] publication (copy enclosed) claims priority from this non-English publication. Enclosed are abstracts of non-English publications \_\_\_\_\_, cited herein as [] respectively. English abstracts are attached to each document. An English abstract of non-English publication , document , may be found on the cover page of the publication. Enclosed is an English translation of non-English publications , cited herein as documents respectively. English translations are attached to each document. The Examiner's attention is directed to related co-pending United States Patent Application Serial Nos.:

Attorney Docket No. NUCL-006/01US Application No. 10/560,377 (US Nat'l. Stage of PCT/US04/19229 Page 3

	, filed	, cited herewith a	as	_; and
		, cited herewith a		
This Informa periods:	tion Disclosure	e Statement is filed with	nin any one of	f the following time
[]	within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);			
[ ]	within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;			
[x]	before the mailing date of a first office action on the merits; or			
[ ]	before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.			
-	•			-noted information and ned. The U.S. Patent and
Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment,				
to our Deposit Accou	•		,	,
Dated: March 21,  USPTO Customer M COOLEY GODWARD K ATTN: Patent Group	No. 58249	By:	For	Ma-Mauf
The Bowen Building 875 15th Street, NW S Washington, DC 2000 Phone: (202) 842-7800	05-2221		Bonnie Weis Reg. No. 43,2	

Fax: (202) 842-7899

Attorney Docket No. Application No. NUCL-006/01US 10/560,377 (US Nat'l. Stage of INFORMATION DISCLOSURE CITATION PCT/US04/19229) several sheets if necessary) Applicants: Catherine J. PACHUK et al. PAGE 1 of 1 MAR 2 1 2007 µРТО Form 1449 Int'l. Filing Date: June 10, 2004 Group Art Unit: To Be Assigned THADEN **U.S. PATENT DOCUMENTS** Initial Filing Date Document No. Date Class Sub-Class Name FOREIGN PATENT DOCUMENTS Document No. Date Class Sub-Class Translation Country 1. WO 03/070918 A2 08/28/2003 WIPO OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.) Holen et al., "Similar behaviour of single-strand and double-strand siRNAs suggests they act through a common 2. RNAi pathway," Nucl. Acids Res. 31:2401-2407 (2003). Macchia, "International Search Report," from PCT/US2004/019229, filed June 10, 2004, 8 pages, European Patent 3. Office, Rijswijk, The Netherlands (mailed September 16, 2005). Examiner Date Considered Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in

conformance and not considered. Include copy of this form with next communication to applicant.